Abeona buys EoE drug candidate APT-1011, raises $30 million as ZEVASKYN sales growNov 9M&AAbeona Therapeutics, IncEupraxia Pharmaceuticals Inc.Updated
Abeona acquires EoE drug candidate ABO-801 from Ellodi, plans $30 million private placementNov 9M&AAbeona Therapeutics, Inc
Abeona reports second-quarter ZEVASKYN growth, expanded treatment center networkAug 13Quarterly updateAbeona Therapeutics, Inc
Abeona Therapeutics, Inc updates registry record NCT07717736: not yet recruitingJul 21Trial updateAbeona Therapeutics, IncRecord notice
Abeona registers long-term safety registry for ZEVASKYN gene therapy in RDEBJul 14Trial updateAbeona Therapeutics, Incpz-cel